Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | CTRC | Q99895 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9058751 | 0.85 | L3MBTL1 (0.59) | L3MBTL1HPGDTSHREPHX2DDB1 | |
| SCHEMBL1488276 | 0.84 | L3MBTL1 (0.56) | L3MBTL1HPGDTSHREPHX2DDB1 | |
| SCHEMBL2223543 | 0.81 | L3MBTL1 (0.60) | L3MBTL1HPGDTSHRDDB1CRBN | |
| SCHEMBL31161862 | 0.81 | ACHE (0.55) | L3MBTL1TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL11175359 | 0.80 | ALDH1A1 (0.49) | L3MBTL1HPGDTSHREPHX2DDB1 | |
| SCHEMBL5642423 | 0.80 | L3MBTL1 (0.62) | L3MBTL1HPGDTSHRDDB1CRBN | |
| SCHEMBL5753697 | 0.79 | SIGMAR1 (0.49) | L3MBTL1KMT2AMEN1POLBGAA | |
| SCHEMBL5743299 | 0.79 | L3MBTL1 (0.66) | L3MBTL1HPGDTSHRDDB1CRBN | |
| SCHEMBL3659094 | 0.78 | CMA1 (0.53) | L3MBTL1CMA1KMT2AMEN1ALDH1A1 | |
| SCHEMBL5075479 | 0.76 | SIGMAR1 (0.56) | F2PLGELANECTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110172061-A | A kind of synthetic method of pyrrolo- [3,4-b] quinoline -1,8- derovatives | 江苏师范大学 | 2019-08-27 | — | — | CN | claimed |
| WO-2024220747-A2 | FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-9977024-B2 | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| US-9977024-B2 | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | THE SCRIPPS RESEARCH INSTITUTE | 2016-07-07 | — | — | US | disclosed |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | THE SCRIPPS RESEARCH INSTITUTE | 2016-07-07 | — | — | US | disclosed |
| WO-2014089546-A1 | TARGETED COVALENT PROBES AND INHIBITORS OF PROTEINS CONTAINING REDOX-SENSITIVE CYSTEINES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-06-12 | — | — | WO | disclosed |
| EP-0245053-B1 | HETEROCYCLIC FUSED TRICYCLIC COMPOUNDS | ICI AMERICAS INC. (US) | 1992-11-25 | — | — | EP | disclosed |
| US-5118688-A | TETRAHYDROPYRIDOQUINOLONE DERIVATIVES USEFUL AS ANXIOLYTIC AGENTS | ICI AMERICAS INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-4975435-A | Certain 1H-pyrrold[3,4-b]quinolin-1-one-9-amino-2,3-dihydro derivatives useful for treating anxiety | ICI AMERICAS INC. (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0245053-A1 | Heterocyclic fused tricyclic compounds | ICI AMERICAS INC. (US) | 1987-11-11 | — | — | EP | disclosed |
| US-4663319-A | LIVER DISORDERS | TANABE SEIYSKU CO., LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0149534-A2 | Novel thioketene derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | PTMS, RSU1, QSOX1 | L3MBTL1 3365/4885HPGD 1331/4885TSHR 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.